Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Biofrontera Inc. amended Existing Warrants Amendment with an institutional investor valued at Amendment to revise exercise price to $3.55 and extend expiration date to November 2, 2028 (effective 2023-10-30).
- Action
- amendment
- Counterparty
- an institutional investor
- Value
- Amendment to revise exercise price to $3.55 and extend expiration date to November 2, 2028
- Effective
- 2023-10-30
Exact text from the filing
On October 30, 2023, in connection with the Purchase Agreement, the Company entered into an amendment to the Existing Warrants (the “ Existing Warrants Amendment ”) pursuant to which the Company agreed, effective November 2, 2023, to (i) revise the exercise price of the Existing Warrants to $3.55 and (ii) extend the date until which the Existing Warrants can be exercised until November 2, 2028.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Biofrontera Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at Gross proceeds of approximately $4.5 million from sale of 1,205,000 shares of common stock and warra (effective 2023-10-30).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Roth Capital Partners, LLC
- Value
- Gross proceeds of approximately $4.5 million from sale of 1,205,000 shares of common stock and warra
- Effective
- 2023-10-30
Exact text from the filing
On October 30, 2023, Biofrontera Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “ Placement Agency Agreement ”) with Roth Capital Partners, LLC (the “ Placement Agent ”) and a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor for the purchase and sale, in a registered public offering by the Company (the “ Public Offering ”) of an aggregate of 1,205,000 shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), or pre-funded warrants to purchase Common Stock in lieu thereof, each of which is coupled with a warrant to purchase one and one-half shares of Common Stock.
View on SEC.gov